Bacillus coagulans MTCC 5856 For The Management of Major Depressive Disorder
AssigneeSami Labs Limited
InventorsMuhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
Life of this patent
Estimating the term…
Abstract
The present invention discloses the use of probiotics for therapeutic management of major depressive disorder (MDD). Specifically, the invention discloses the method of therapeutically managing MDD in mammals with Irritable bowel syndrome using probiotic strain Bacillus coagulans MTCC 5856.
Claims9
A method of therapeutically managing major depressive disorder in human subjects, said method comprising step of administering Bacillus coagulans MTCC 5856 to the said subjects experiencing symptoms of major depressive disorder.
(canceled)
A method of reducing serum myeloperoxidase levels in human subjects experiencing symptoms of major depressive disorder said method comprising step of administering Bacillus coagulans MTCC 5856 to said subjects experiencing symptoms of major depressive disorder.
(canceled)
Dependencies are inferred from the claim text.